Search | Clinical Trials Finder

Conditions: Diabetes, Type I
Interventions: Technosphere Insulin, Active comparator; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 589 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 61
States / cities: Mobile, Alabama • Chandler, Arizona • Chula Vista, California + 48 more

Conditions: Symptomatic Neurogenic Orthostatic Hypertension, nOH
Interventions: Ampreloxetine <Dose A>, Ampreloxetine <Dose B>, Ampreloxetine Placebo, Moxifloxacin, Moxifloxacin Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Ischemic Stroke
Interventions: PF-03049423, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 32
States / cities: Birmingham, Alabama • Deerfield Beach, Florida • Fort Lauderdale, Florida + 12 more

Conditions: Psoriasis
Interventions: CD 2027, Calcitriol Vehicle; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Fridley, Minnesota • Nashville, Tennessee

Conditions: Parapsoriasis
Interventions: Apremilast, Placebo, Placebo-Apremilast; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 26
States / cities: Birmingham, Alabama • Fremont, California • Los Angeles, California + 21 more

Conditions: Chronic Kidney Diseases, Hypertension
Interventions: KBP-5074 0.25 mg tablet, KBP-5074 0.5 mg tablet; Drug
Lead sponsor: KBP Biosciences; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Princeton, New Jersey • Morrisville, North Carolina

Conditions: Open-angle Glaucoma or Ocular Hypertension
Interventions: DE-117 ophthalmic solution, latanoprost ophthalmic solution, Placebo; Drug · Other
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 7
States / cities: Newport Beach, California • Morrow, Georgia • Kansas City, Missouri + 4 more

Conditions: Alpha1-proteinase Inhibitor Deficiency, Emphysema
Interventions: Alpha1-proteinase inhibitor, Placebo; Biological · Other
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 4
States / cities: Denver, Colorado • Miami, Florida • Hershey, Pennsylvania + 1 more

Conditions: Rheumatoid Arthritis (RA)
Interventions: Abatacept, Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion), Upadacitinib, Placebo for upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 657 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 44
States / cities: Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more

Conditions: Uterine Fibroids
Interventions: Vilaprisan (BAY1002670), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 52
States / cities: Birmingham, Alabama • Arcadia, California • Cerritos, California + 43 more

Conditions: Asthma
Interventions: AS MDI 90 μg, AS MDI 180 µg, Placebo MDI, Proventil 90 μg, Proventil 180 μg; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 10
States / cities: Rolling Hills Estates, California • Stockton, California • Winter Park, Florida + 7 more

Conditions: Diabetes Mellitus, Type 2
Interventions: albiglutide, albiglutide uptitration, placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 247
States / cities: Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 205 more

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution, Topical ultra-low dose of DE-126 Ophthalmic Solution, Topical low dose of DE-126 Ophthalmic Solution, Topical medium dose of DE-126 Ophthalmic Solution, Topical high dose of DE-126 Ophthalmic Solution, 0.005% Latanoprost Ophthalmic Solution; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 12
States / cities: Artesia, California • Mission Hills, California • Newport Beach, California + 9 more

Conditions: Common Wart
Interventions: A-101 Topical Solution, A-101 Vehicle Solution; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 8 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 17
States / cities: Scottsdale, Arizona • Rogers, Arkansas • San Diego, California + 13 more

Conditions: Hypertension, Metabolic Syndrome
Interventions: MANP; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Detrusor Overactivity, Overactive Bladder
Interventions: Placebo, solifenacin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: New York, New York • West Reading, Pennsylvania

Conditions: Infection, Human Immunodeficiency Virus
Interventions: BMS-663068 400 mg, BMS-663068 800 mg, BMS-663068 600 mg, BMS-663068 1200 mg, Raltegravir 400 mg, Tenofovir 300 mg, Ritonavir 100 mg, Atazanavir 300 mg; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 13
States / cities: San Francisco, California • Washington D.C., District of Columbia • Coral Gables, Florida + 9 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Placebo, PF-04937319; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 3
States / cities: Phoenix, Arizona • Cypress, California • Miami, Florida

Conditions: Dry Eye Disease
Interventions: INV-102, Vehicle; Drug
Lead sponsor: Invirsa, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Rush, New York

Conditions: Acute Otitis Media
Interventions: AR01, Placebo Comparator; Drug
Lead sponsor: Arbor Pharmaceuticals, Inc.; Industry
Eligibility: 2 Months to 18 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 21
States / cities: Phoenix, Arizona • Bakersfield, California • Fresno, California + 16 more

Conditions: Type 2 Diabetes, Hyperlipidemia
Interventions: Colesevelam HCl, rosiglitazone maleate, sitagliptin phosphate; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 20
States / cities: La Mesa, California • Los Angeles, California • Los Gatos, California + 17 more

Conditions: Uterine Fibroids, Heavy Menstrual Bleeding
Interventions: OBE2109, Placebo to match OBE2109, Placebo to match Add-back, Add-back; Drug
Lead sponsor: ObsEva SA; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 526 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 116
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 93 more

Conditions: Pemphigus
Interventions: Infliximab, Placebo Comparator; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 4
States / cities: Los Angeles, California • Iowa City, Iowa • Durham, North Carolina + 1 more

Conditions: Adenomatous Polyposis Coli
Interventions: Celecoxib, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 23
States / cities: Chicago, Illinois • Ann Arbor, Michigan • Omaha, Nebraska + 16 more

Search by objective public record fields.

Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes

Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis

A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.

Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease

Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)

Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma

Safety and Efficacy Study of Albiglutide in Type 2 Diabetes

A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

A Phase2 of A-101 Topical Solution in Subjects With Common Warts

MANP in Hypertension and Metabolic Syndrome

Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.

HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus

Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease

Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)

Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin

Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Use of Infliximab for the Treatment of Pemphigus Vulgaris

Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)